Validation of Red Cell Distribution Width As a COVID-19 Severity Screening Tool

Pouladzadeh, Mandana; Safdarian, Mehdi; Choghakabodi, Parastoo Moradi; Amini, Fatemeh; Sokooti, Alireza

doi:10.2144/fsoa-2020-0199

Cited by 17 publications

(19 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another possible mechanism SARS-CoV-2 spike protein binds to the CD147 receptor that plays a role for mediating SARS-CoV-2 invasion and diffusion among other cells; the CD147 receptor is also determinative of the blood group system. The blockage of CD147 by spike protein leads to the elective trapping of RBCs in the spleen and which eventually RDW elevation [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

A new haematocytometric index: Predicting severity and mortality risk value in COVID-19 patients

et al. 2021

View full text Add to dashboard Cite

Introduction Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 virus, is a major public health concern spanning from healthy carriers to patients with life-threatening conditions. Although most of COVID-19 patients have mild-to-moderate clinical symptoms, some patients have severe pneumonia leading to death. Therefore, the early prediction of disease prognosis and severity is crucial in COVID-19 patients. The main objective of this study is to evaluate the haemocytometric parameters and identify severity score associated with SARS-CoV-2 infection. Methods Clinical and laboratory records were retrospectively reviewed from 97 cases of COVID-19 admitted to hospitals in Istanbul, Turkey. The patient groups were subdivided into three major groups: Group 1 (Non-critical): 59 patients, Group 2 (Critical-Survivors): 23 patients and Group 3 (Critical-Non-survivors):15 patients. These data was tested for correlation, including with derived haemocytometric parameters. The blood analyses were performed the Sysmex XN-series automated hematology analyser using standard laboratory protocols. All statistical testing was undertaken using Analyse-it software. Results 97 patients with COVID-19 disease and 935 sequential complete blood count (CBC-Diff) measurements (days 0–30) were included in the final analyses. Multivariate analysis demonstrated that red cell distribution width (RDW) (>13.7), neutrophil to lymphocyte ratio (NLR) (4.4), Hemoglobin (Hgb) (<11.4 gr/dL) and monocyte to neutrophil ratio (MNR) (0.084) had the highest area under curve (AUC) values, respectively in discrimination critical patients than non-critical patients. In determining Group 3, MNR (<0.095), NLR (>5.2), Plateletcount (PLT) (>142 x103/L) and RDW (>14) were important haemocytometric parameters, and the mortality risk value created by their combination had the highest AUC value (AUC = 0.911, 95% CI, 0886–0.931). Trend analysis of CBC-Diff parameters over 30 days of hospitalization, NLR on day 2, MNR on day 4, RDW on day 6 and PLT on day 7 of admission were found to be the best time related parameters in discrimination non-critical (mild-moderate) patient group from critical (severe and non-survivor) patient group. Conclusion NLR is a strong predictor for the prognosis for severe COVID-19 patients when the cut-off chosen was 4.4, the combined mortality risk factor COVID-19 disease generated from RDW-CV, NLR, MNR and PLT is best as a mortality haematocytometric index.

show abstract

Section: Discussionmentioning

confidence: 99%

A new haematocytometric index: Predicting severity and mortality risk value in COVID-19 patients

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Elevated RDW levels imply that the size distribution of red blood cells yields a greater variation than normal RDW values and signal bone marrow dysfunction induced by vitamin B12, folate, or iron deficiencies [10]. Pouladzadeh et al divided 331 patients with COVID-19 into 'severe' and 'non-severe' cohorts and evaluated their RDW-SD levels [11].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the Diagnostic Value of Hematologic Parameters and Ratios in SARS-CoV-2 VOC-202012/01 Mutant Population

Seyit¹,

Avcı²,

Yılmaz³

et al. 2022

Cureus

View full text Add to dashboard Cite

In this study, we set out to study possible differences between individuals with and without VOC 202012/01 variant by using less costly complete blood count analytes and quickly analyzing the samples and ratios derived from these analytes. For this purpose, we assessed neutrophil, lymphocyte, platelet, and Red Blood Cell Distribution Width-Standard Deviation (RDW-SD) levels among complete blood count parameters (CBC) (identification and count of red blood cell, neutrophil, eosinophil, basophil, lymphocyte, monocyte, platelet) as well as the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR). MethodsA retrospective cross-sectional study was performed over the course of two months (from May to June 2021) on 212 patients who presented to the emergency department of a tertiary hospital with Covid-19 symptoms and took SARS-CoV2 PCR and CBC tests. The polymerase chain reaction (PCR)-confirmed SARS-CoV2 positive patients and their hospitalization data were gathered from the public health management system. Their VOC-202012/01 mutation status was also confirmed by this system. ResultsRDW-SD, RDW, NLR, and PLR indexes, as well as C-reactive protein (CRP), and lactate dehydrogenase (LDH) values, were higher in the patients with VOC-202012/01 mutation (p<0.0001) than those without mutation, while hemoglobin and hematocrit counts and ratio, as well as eosinophil and lymphocyte counts, remained lower in the patients with mutation (p<0.0001). ConclusionNLR and RLP ratios derived from hematological parameters and models based on these ratios and RDW-SD are cheaper and more widely used. Our study suggests that the hematological analytes, the ratios obtained from these analytes, and the models created through these ratios in patients presenting to the ED with COVID-19-like symptoms and having positive reverse transcription polymerase chain reaction (RT-PCR) test results were significantly different in those with and without the VOC-202012/01 mutation. The bottom line is that they can serve as reliable predictors in the assessment of patients with the VOC-202012/01 mutation.

show abstract

“…M2 macrophages can also play an important role in proliferation, angiogenesis, and EMT induction in tumor cells by secreting factors such as EGF, VEGF, and PDGF; it subsequently leads to their resistance to chemotherapy drugs [ 35 , 36 ]. Secreted EGF by M2 macrophages induces RAS/RAF/MAPK, PI3K/AKT and PLC/PKC/CAMK signaling in the downstream of EGF/EGFR signal transmission pathway in the tumor cells, and via binding to the EGFR receptor on the surface of cited cells; it subsequently can be effective to create survival and proliferation of malignant cells through the mentioned signaling pathways [ 37 ] (Fig.…”

Section: Aberrant Function Of Innate Immune Cellsmentioning

confidence: 99%

The effect of COVID-19 derived cytokine storm on cancer cells progression: double-edged sword

et al. 2021

View full text Add to dashboard Cite

Objective Severe acute respiratory syndrome coronavirus 2 (SARS-COV2) was first detected in Wuhan, China in December, 2019. The emerging virus causes a respiratory illness, that can trigger a cytokine storm in the body. Method Cytokine storm in patient’s body is associated with severe forms of disease. It is one of the main complications of coronavirus disease-2019 (COVID-19), in which immune cells play a major role. Studies have shown immune cells in the tumor environment can be effective to induce resistance to chemotherapy in cancer patients. Result Therefore, considering the role of immune cells to induce cytokine storm in COVID-19 patients, and their role to cause resistance to chemotherapy, they are effective on disease progression and creation of severe form of disease. Conclusion By examining the signaling pathways and inducing resistance to chemotherapy in tumor cells and the cells affect them, it is possible to prevent the occurrence of severe forms of the disease in cancer patients with COVID-19; it is applicable using target therapy and other subsequent treatment strategies.

show abstract

Validation of Red Cell Distribution Width As a COVID-19 Severity Screening Tool

Cited by 17 publications

References 42 publications

A new haematocytometric index: Predicting severity and mortality risk value in COVID-19 patients

A new haematocytometric index: Predicting severity and mortality risk value in COVID-19 patients

Evaluation of the Diagnostic Value of Hematologic Parameters and Ratios in SARS-CoV-2 VOC-202012/01 Mutant Population

The effect of COVID-19 derived cytokine storm on cancer cells progression: double-edged sword

Contact Info

Product

Resources

About